Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 8/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7253909 | 0.87 | ALDH1A1 (0.42) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL7254218 | 0.86 | MAPT (0.49) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL5798941 | 0.81 | MAPT (0.51) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6609547 | 0.77 | MAPT (0.48) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL7253960 | 0.76 | PDE4B (0.52) | KMT2AMAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL6615567 | 0.73 | MAPT (0.44) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6610665 | 0.72 | MAPT (0.43) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6605271 | 0.72 | KMT2A (0.41) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL6612265 | 0.72 | ALDH1A1 (0.43) | KMT2AMEN1MAPTALDH1A1KDM4E | |
| SCHEMBL73947 | 0.71 | PDE4D (0.42) | KMT2AMEN1MAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952832-B1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LTD (GB) | 2008-08-27 | — | — | EP | disclosed |
| US-6642254-B2 | Administering compounds, e.g., 8-methoxy-2-trifluoromethylquinoline-5-carboxylic acid (3,5-dichloro-1-oxypyridin-4-yl)amide for therapy of disease state that is capable of being modulated by inhibition of phosphodiesterase | DARWIN DISCOVERY, LTD. (GB) | 2003-11-04 | — | — | US | disclosed |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2002-12-05 | — | — | US | disclosed |
| US-6410559-B2 | 3,5-DISUBSTITUTED-(OXYPYRIDINE-4-YL)AMIDE DERIVATIVES USED AS PHOSPHODIESTERASE IV OR TUMOR NECROSIS FACTOR INHIBITOR TO TREAT INFLAMMATORY DISEASE OR AUTOIMMUNE DISEASE | DARWIN DISCOVERY, LTD. (GB) | 2002-06-25 | — | — | US | disclosed |
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | DYKE HAZEL JOAN (GB) | 2001-09-27 | — | — | US | disclosed |
| US-6262070-B1 | E.G., 8-METHOXY-2-TRIFLUOROMETHYLQUINOLINE-5-CARBOXYLIC ACID(3,5-DICHLORO-1-OXYPYRIDIN-4-YL)AMIDE; TREATMENT OF CHRONIC OBSTRUCTIVE AIRWAYS DISEASE | DARWIN DISCOVERY LTD. (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1045845-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | Darwin Discovery Limited (GB) | 2000-10-25 | — | — | EP | disclosed |
| WO-2000026208-A1 | N-OXIDES OF HETEROCYCLIC COMPOUNDS WITH TNF AND PDE-IV INHIBITING ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| EP-0952832-A1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | Darwin Discovery Limited (GB) | 1999-11-03 | — | — | EP | disclosed |
| US-5804588-A | TREATING DISEASES THAT ARE MODULATED BY INHIBITION OF PHOSPHODIESTERASE IV OR TUMOUR NECROSIS FACTOR | CHIROSCIENCE LIMITED (GB) | 1998-09-08 | — | — | US | disclosed |
| WO-1997044036-A1 | QUINOLINE CARBOXAMIDES AS TNF INHIBITORS AND AS PDE-IV INHIBITORS | DARWIN DISCOVERY LIMITED (GB) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025049-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | KMT2A 4306/4885MEN1 1624/4885MAPT 4689/4885 |
| US-20020183358-A1 | Heterocyclic compounds and their therapeutic use | CBR1, CBR3, CYC1 | KMT2A 4306/4885MEN1 1624/4885MAPT 4689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.